Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt (2020 - 2022)

Historic Short term Debt for Anika Therapeutics (ANIK) over the last 7 years, with Q2 2022 value amounting to $4.3 million.

  • Anika Therapeutics' Short term Debt fell 7442.21% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.3 million, marking a year-over-year decrease of 7442.21%. This contributed to the annual value of $4.3 million for FY2021, which is 6703.59% down from last year.
  • Latest data reveals that Anika Therapeutics reported Short term Debt of $4.3 million as of Q2 2022, which was down 7442.21% from $4.3 million recorded in Q1 2022.
  • Anika Therapeutics' 5-year Short term Debt high stood at $24.8 million for Q1 2021, and its period low was $4.3 million during Q3 2021.
  • Over the past 3 years, Anika Therapeutics' median Short term Debt value was $4.3 million (recorded in 2021), while the average stood at $10.3 million.
  • In the last 5 years, Anika Therapeutics' Short term Debt tumbled by 6703.59% in 2021 and then plummeted by 8268.22% in 2022.
  • Anika Therapeutics' Short term Debt (Quarter) stood at $13.1 million in 2020, then plummeted by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Its Short term Debt stands at $4.3 million for Q2 2022, versus $4.3 million for Q1 2022 and $4.3 million for Q4 2021.